Please try another search
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop...
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cidara...
On Thursday, Needham raised the price target on shares of Cidara Therapeutics (NASDAQ:CDTX) to $25.00, a significant increase from the previous target of $3.00. The investment firm...
Investors in Cidara Therapeutics, Inc. (NASDAQ:CDTX) need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 20th 2018 $7.50...
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is expected to report third-quarter 2017 results around Nov 8, before market opens. Last quarter, Merrimack missed bottom-line...
Investors are always looking for stocks that are poised to beat at earnings season and Cidara Therapeutics, Inc. (NASDAQ:CDTX) may be one such company. The firm has earnings...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Sell | Sell | Sell | Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Neutral | Strong Sell | Strong Sell |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Completed Patterns | |||||
Abandoned Baby Bullish | 1D | 1 | May 02, 2024 | ||
Morning Doji Star | 1D | 1 | May 02, 2024 | ||
Tri-Star Bullish | 15 | 1 | May 03, 2024 03:30PM | ||
Bullish doji Star | 1D | 2 | May 01, 2024 | ||
Tri-Star Bearish | 15 | 3 | May 03, 2024 02:45PM |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Apple | 183.36 | 187.00 | 182.66 | +10.33 | +5.97% | 153.44M | 16:00:07 | ||
Alibaba ADR | 81.33 | 81.37 | 79.70 | +1.00 | +1.24% | 18.95M | 15:59:59 | ||
Coinbase Global | 223.25 | 232.25 | 216.55 | -5.60 | -2.45% | 13.66M | |||
NVIDIA | 887.83 | 892.81 | 870.40 | +29.66 | +3.46% | 39.02M | 16:00:07 | ||
Block | 69.47 | 76.50 | 68.98 | -0.83 | -1.18% | 28.73M | 15:59:59 | ||
Nio A ADR | 5.570 | 5.580 | 5.330 | -0.020 | -0.36% | 54.31M | 15:59:59 | ||
Tesla | 181.14 | 184.78 | 178.43 | +1.13 | +0.63% | 74.86M | 16:00:07 | ||
Palantir | 23.32 | 23.53 | 22.91 | +0.77 | +3.44% | 54.49M | 16:00:07 | ||
Microsoft | 406.66 | 407.15 | 401.86 | +8.82 | +2.22% | 16.42M | 16:00:01 | ||
Meta Platforms | 452.05 | 454.16 | 444.00 | +10.37 | +2.35% | 15.95M |
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review